These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33124806)

  • 1. Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Yan L; Banuelos CA; Mawji NR; Patrick BO; Sadar MD; Andersen RJ
    J Nat Prod; 2021 Mar; 84(3):797-813. PubMed ID: 33124806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.
    Sadar MD; Williams DE; Mawji NR; Patrick BO; Wikanta T; Chasanah E; Irianto HE; Soest RV; Andersen RJ
    Org Lett; 2008 Nov; 10(21):4947-50. PubMed ID: 18834139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
    Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
    PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
    Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
    Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
    Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of
    Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
    J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
    Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
    Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
    Sugawara T; Baumgart SJ; Nevedomskaya E; Reichert K; Steuber H; Lejeune P; Mumberg D; Haendler B
    Int J Cancer; 2019 Sep; 145(5):1382-1394. PubMed ID: 30828788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
    Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
    J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity.
    Meimetis LG; Williams DE; Mawji NR; Banuelos CA; Lal AA; Park JJ; Tien AH; Fernandez JG; de Voogd NJ; Sadar MD; Andersen RJ
    J Med Chem; 2012 Jan; 55(1):503-14. PubMed ID: 22148427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
    Nakka M; Agoulnik IU; Weigel NL
    Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
    Ji Y; Zhang R; Han X; Zhou J
    Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
    Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.